Smith & Nephew Stock Rating Reaffirmed by Numis Securities Ltd (SN)
Smith & Nephew (LON: SN)‘s stock had its “add” rating restated by equities researchers at Numis Securities Ltd in a report issued on Wednesday. They currently have a $12.39 (800 GBX) target price on the stock.
Shares of Smith & Nephew opened at 703.50 on Wednesday. Smith & Nephew has a 52 week low of GBX 567.50 and a 52 week high of GBX 738.092. The stock’s 50-day moving average is currently GBX 681.0. The company’s market cap is £6.310 billion.
A number of other firms have also recently commented on SN. Analysts at Jefferies Group raised their price target on shares of Smith & Nephew from $11.58 to $12.52 in a research note to investors on Tuesday, February 12th. They now have a “buy” rating on the stock. Separately, analysts at UBS AG raised their price target on shares of Smith & Nephew from $19.57 to $20.35 in a research note to investors on Monday, February 11th. They now have a “buy” rating on the stock. Finally, analysts at Credit Suisse raised their price target on shares of Smith & Nephew from $10.80 to $11.35 in a research note to investors on Monday, February 11th. They now have a “neutral” rating on the stock.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (which includes arthroscopic procedures referred to as sports medicine) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.